Stock MNKD MANNKIND CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
4.26 USD +0.71% Intraday chart for MannKind Corporation +3.65% +17.03%
Apr. 29 MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment MT
Apr. 29 MannKind Gets FDA Clearance for Clofazimine IND Application DJ

Evolution of the average Target Price on MannKind Corporation

Price target over the last 5 years

History of analyst recommendation changes

f3c58879b76424006ec116629ef4.u6JUB3sI2ypkmUN9NCAdPGh16zqQ5rLplIuMQpr3tl0.5MdnUThMqXwJoQEWZ2coaTojj1nKnuGOrdnnOs7H82j9wD8_GUeaWx7KFg~80324764ad9eec0156476ab28b9af22a

Analyst Recommendations on MannKind Corporation

Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality MT
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating MT
SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating MT
HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating MT
MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share MT
MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating MT
MANNKIND : BTIG Research Adjusts MannKind PT to $8 From $4, Maintains Buy Rating MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $7 From $3, Maintains Outperform Rating MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $3 From $2.50, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.26 USD
Average target price
7.083 USD
Spread / Average Target
+66.28%
High Price Target
10 USD
Spread / Highest target
+134.74%
Low Price Target
5 USD
Spread / Lowest Target
+17.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MannKind Corporation

Oppenheimer
Wedbush
HC Wainwright
SVB Securities LLC
RBC Capital Markets
SVB Leerink

Ratings for MannKind Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. Consensus MannKind Corporation